Back to RVMD Overview
NMS · Valuation Lab
RVMD
Revolution Medicines, Inc.
Last$197.30
Market cap41.9B
EV/EBITDA-29.4x
Intrinsic value
$6.92
MoS -2751.8% · Overvalued
Assuming 15.0% FCF margin and 10.0% Y1–5 growth.
Upside to price
EV (DCF)0
Terminal share0%
Expected IV$6.92
Probability weights
Projected free cash flows
Stage FCF path with present values · terminal 0% of EV
PV of stage FCFs0
PV of terminal value0
Enterprise value0
Net cash / (debt)1.5B
Equity value1.5B
Intrinsic value / share$6.92
| Year | Revenue | FCF | PV | DF |
|---|---|---|---|---|
| Y1 | 0 | 0 | 0 | 90.0% |
| Y2 | 0 | 0 | 0 | 81.0% |
| Y3 | 0 | 0 | 0 | 72.8% |
| Y4 | 0 | 0 | 0 | 65.5% |
| Y5 | 0 | 0 | 0 | 59.0% |
| Y6 | 0 | 0 | 0 | 53.1% |
| Y7 | 0 | 0 | 0 | 47.7% |
| Y8 | 0 | 0 | 0 | 43.0% |
| Y9 | 0 | 0 | 0 | 38.7% |
| Y10 | 0 | 0 | 0 | 34.8% |
| Terminal | — | — | 0 | — |
Educational DCF model only — not financial advice. Terminal value and assumptions dominate results; verify filings and run your own diligence.